Skip to main content

Anti-Rheumatic Rx

      Happening now, new guidelines for mgmt. A few highlights:

      Recommend prompt GC therapy, pulse x1-3d followed by oral pr
      1 month ago
      Happening now, new guidelines for mgmt. A few highlights: Recommend prompt GC therapy, pulse x1-3d followed by oral pred (<0.5mg/kg/d) w/taper to <5mg by 6 months Aligns with EULAR recs for a much-lower dose than most clinicians currently doing #ACR24 @RheumNow https://t.co/B71i7FBYlQ
      Abstract 2503: Clofutriben (HSD-1 inhibitor) minimizes adrenal suppression. Adding clofutriben to prednisolone boosts A
      Abstract 2503: Clofutriben (HSD-1 inhibitor) minimizes adrenal suppression. Adding clofutriben to prednisolone boosts ACTH & cortisol levels with fewer patients with suppressed morning cortisol (≤5.0 mg/dL) (34% vs 14%). @RheumNow #ACR24 #GCTox
      If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options
      If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much @RheumNow #ACR24 https://t.co/jn52ujtspo
      Hyrich:
      ETN originator vs biosimilar initiation
      - DAS28 - no signif change at B/L, 6mo, 12 mo.

      Switch?
      Matched pts in E
      1 month ago
      Hyrich: ETN originator vs biosimilar initiation - DAS28 - no signif change at B/L, 6mo, 12 mo. Switch? Matched pts in ETN switch v cont originator - good b/l control on Rx -DAS28 maintained w switch 10% did go back to originator, felt less good tho similar DAS #ACR24 @RheumNow https://t.co/RHRit5CtUu
      Early observational data suggesting JAK inhibitors can play a role in TAK tx

      We have seen this with UPA in GCA this con
      Early observational data suggesting JAK inhibitors can play a role in TAK tx We have seen this with UPA in GCA this conference… time for SELECT-TAK ! @RheumNow #ACR24 https://t.co/B2Wa8sOFTp
      Late-Breaking Abstract L07

      The CLASS Project introduces new global classification criteria for Anti-Synthetase Syndrom
      Late-Breaking Abstract L07 The CLASS Project introduces new global classification criteria for Anti-Synthetase Syndrome (ASSD). Using the gold standard dataset, the key findings were: ✅ Definite ASSD: Sensitivity 94.3%, Specificity 99.7% ✅ Probable ASSD: Sensitivity 97.5%,… https://t.co/PtciIMTSsu https://t.co/jvJv2VNvHx
      Risks for HCQ cardiotoxicity:
      👉>5 yrs use
      👉>5 mg/kg/d (cumulative dose >500,000 mg)
      👉CKD
      👉use NSA
      1 month ago
      Risks for HCQ cardiotoxicity: 👉>5 yrs use 👉>5 mg/kg/d (cumulative dose >500,000 mg) 👉CKD 👉use NSAID 👉preexisting heart dz 👉presence of ocular, derm, SkM toxicity - Dr M Garschik #ACR24 @rheumnow https://t.co/LFobgls4jm
      #2259💊 Anti-Obesity Meds in RA📊 152 RA patients on semaglutide/tirzepatide 🔑 Findings💥Significant ⬇?

      #2259 💊 Anti-Obesity Meds in RA 📊 152 RA patients on semaglutide/tirzepatide 🔑 Findings 💥Significant ⬇️weight, BMI, ESR, CRP, lipids, pain VAS 💥Improved CVD risk ⛔ 15% GI side effects, 27% discontinued 🔎Study of impact on RA outcomes needed #ACR24 @RheumNow #ACRBest https://t.co/6LCTZl5173

      Dr. @karen_kc123 discusses the results of the VITAL study.
      - Long term use of Vit D3 2000IU was safe and decreased the i
      1 month ago
      Dr. @karen_kc123 discusses the results of the VITAL study. - Long term use of Vit D3 2000IU was safe and decreased the incidence of all autoimmune dses by 22%. - It took a while to work but the effect dissipates once discontinued. @RheumNow #ACR24 @rheumarhyme https://t.co/mnwRsdZ06N
      A#2532
      Pre-existing AID for immunoRx?
      Excluded from trials
      4 prior studies showed no diff in mortality w AID
      Propensity-
      1 month ago
      A#2532 Pre-existing AID for immunoRx? Excluded from trials 4 prior studies showed no diff in mortality w AID Propensity-matched cohort study Followed median 250 days Hazard ratio: 1.07 (unmatched), 0.97 (matched) - no diff. Mortality about 40% in grps @RheumNow #ACR24 https://t.co/zyVCPts6s6
      ×